BRAF and neoplasm: This suggests that excessive tumor-generated HB-EGF might prevent PEPDG278D from binding to EGFR, and also suggests that EGFR signaling remains important to the tumors carrying activating mutations of KRAS, BRAF and/or PIK3CA.